Filing Flows › Rigel Pharmaceuticals (RIGL) › Q1 2026
Rigel Pharmaceuticals (RIGL) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 5, 2026
Rigel Pharmaceuticals (RIGL) reported revenue of $58.8M for the first quarter 2026 (Q1 2026), +10% from a year earlier and -16% from the quarter before. Operating margin was 20.2%, net earnings $8.7M (14.7% of revenue).
Rigel Pharmaceuticals, Q1 2026: revenue $58.8M (+10% year over year), operating margin 20.2%, net earnings $8.7M, operating cash flow $2.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $58.8M | -16% | +10% |
| Operating profit | $11.9M | -49% | -7% |
| Net earnings | $8.7M | -97% | -24% |
| Operating cash flow | $2.7M | -88% | — |
What changed
Revenue was $58.8M in Q1 2026, up 10% year over year and down 16% from the previous quarter. Product sales, net was the largest line at 93% of revenue. Product sales, net added $11.4M year over year (up 26%), 207% of the total change. Contract revenues from collaborations and other declined 60%.
Operating profit was $11.9M, a 20.2% margin (down 3.7 points year over year). Operating profit fell $888K even though revenue rose $5.5M versus Q1 2025, so costs grew faster than sales. Total costs grew 16% against revenue growth of 10%. The fastest-growing cost line was Research & development (+38%). Net earnings were $8.7M, down 24% year over year. The effective tax rate was 25.8%.
Operating cash flow was $2.7M, 31% of net earnings. Non-cash charges added back $597K of depreciation and amortization and $3.5M of share-based compensation. Working capital and other items used $10.0M.
Questions
What was Rigel Pharmaceuticals' revenue in the first quarter 2026?
Rigel Pharmaceuticals (RIGL) reported revenue of $58.8M for the first quarter 2026 (Q1 2026), +10% from a year earlier and -16% from the quarter before.
Was Rigel Pharmaceuticals profitable in the first quarter 2026?
Operating profit was $11.9M (20.2% of revenue) and net earnings $8.7M.